Inogen Q2 Earnings: Revenue Up 4%, Raises Full-Year Outlook

Inogen Inc reported a 4% YoY increase in revenue to $92.3 million in Q2 2025, driven by growth in international and domestic business-to-business sales. The company launched new products, including the Voxi 5 stationary oxygen concentrator and Inogen Patient Portal, and raised its full-year 2025 revenue outlook to $354-$357 million, reflecting 6% growth. Inogen aims to reach adjusted EBITDA breakeven for the year.

Inogen Inc (INGN) reported its second-quarter 2025 financial results, showing a 4% year-over-year (YoY) increase in revenue to $92.3 million. This growth was driven primarily by higher demand from international and domestic business-to-business (B2B) customers. The company also launched new products, including the Voxi 5 stationary oxygen concentrator and Inogen Patient Portal, further expanding its product portfolio.

In addition to the revenue growth, Inogen reported a GAAP net loss of $4.2 million, an improvement from the prior period's $5.6 million loss. The company also achieved adjusted EBITDA of $2.1 million for the second quarter, marking the second consecutive quarter of positive adjusted EBITDA. Operating cash flow was $4.4 million, strengthening the company's cash position to $123.7 million as of June 30, 2025.

The company's strong performance in the first half of 2025 has led Inogen to raise its full-year 2025 revenue outlook to $354 million to $357 million, reflecting 6% growth at the midpoint of the range. This increase is driven by the expected contributions from the Voxi 5 launch and the Inogen Patient Portal. Inogen aims to reach adjusted EBITDA breakeven for the year.

The company's earnings call provided further insights into its financial performance and future outlook. Kevin Smith, President and CEO, highlighted the company's turnaround strategy, noting six consecutive quarters of mid-single-digit revenue growth and two quarters of positive adjusted EBITDA. Mike Fork, CFO, noted that second-half growth is expected to be 7% at the midpoint of guidance, with mid-single-digit growth in Q3 and low double-digit growth in Q4.

Inogen's strategy to expand its product portfolio and market reach, along with its focus on operational enhancements and cost management, is expected to drive future growth and profitability. The company is well-positioned to continue its path towards double-digit growth and sustainable profitability.

References:
[1] https://finance.yahoo.com/news/inogen-inc-ingn-q2-2025-074033972.html
[2] https://www.businesswire.com/news/home/20250807376840/en/Inogen-Announces-Second-Quarter-2025-Financial-Results